Gut microbiome dysbiosis
Conditions
Interventions
During the first 7 da7s of the study period, all participants will be provided
with the antibiotic vancomycin. Participants will be asked to take two capsules
of 250 mg three times per day for 7 day
Sponsors
Universiteit Maastricht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Healthy overweight/obese (BMI: 25-40 kg/m^2) Caucasian adults (age: 20-65 years), male and female, with a stable body weight (
Exclusion criteria
Exclusion criteria: - Known allergic reaction to vancomycin or other glycopeptide antibiotics; - Pre-diabetes, diabetes mellitus, cardiovascular disease, kidney disease, hearing disorders, cancer, asthma or bronchitis, liver malfunciton, diseases affecting glucose tolerance, major illness with a life expectancy 20 cigarettes per day; - Regular use of laxation products; - Use of antibiotics in the past 3 months; - Regular supplementation of pre- or probiotics products, use of pre- or probiotics 3 months prior to the start of the study; - Plans to lose weight or currently following a hypocaloric diet; - Following a vegan diet; - Participation in organized sports activities for > 3 hours per week. - Suffering from hearing loss or other hearing problems. - Currently pregnant, planning to become pregnant or currently breastfeeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main outcome parameter will be microbiome resilience, which will be described as the change in gut microbiome composition and activity between baseline, after antibiotics use and during/after 2'-FL/placebo supplementation. This parameter will be investigated at six different timepoints throughout the study. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary outcome parameters of the study are BMI, waist-to-hip ratio, body composition, glucose tolerance, fat metabolism, adipose tissue gene and protein expression and levels of short-chain fatty acids, inflammatory markers and satiety hormones in the blood. These parameters will be investigated on three different timepoints during the study: at baseline, after antibiotics use and after the supplementation period. | — |
Countries
Netherlands
Outcome results
None listed